Rice Hall James & Associates LLC Invests $2.91 Million in iRadimed Corporation $IRMD

Key Points

• Rice Hall James & Associates bought 30,444 iRadimed shares worth approximately $2.91 million, while institutional investors collectively own 92.34% of the company.
• iRadimed exceeded quarterly expectations with EPS of $0.46 versus the $0.44 consensus and revenue of $20.47 million. Analysts maintain a “Moderate Buy” consensus with an average price target of $120, though two research firms recently downgraded the stock to “Hold.”
• The company declared a quarterly dividend of $0.20, equivalent to $0.80 annually and a 0.9% yield. Shares opened at $87.55, down 0.5%, and the CEO separately sold 2,500 shares under a pre-arranged trading plan.

Rice Hall James & Associates LLC purchased a new stake in iRadimed Corporation (NASDAQ:IRMD - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 30,444 shares of the medical equipment provider's stock, valued at approximately $2,909,000. Rice Hall James & Associates LLC owned 0.24% of iRadimed as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of IRMD. Baader Bank Aktiengesellschaft acquired a new position in iRadimed in the fourth quarter valued at approximately $595,000. Bridge City Capital LLC grew its holdings in shares of iRadimed by 19.4% during the fourth quarter. Bridge City Capital LLC now owns 70,854 shares of the medical equipment provider's stock valued at $6,893,000 after purchasing an additional 11,509 shares during the last quarter. RFG Advisory LLC acquired a new stake in shares of iRadimed during the 4th quarter worth approximately $1,594,000. Arrowstreet Capital Limited Partnership raised its position in shares of iRadimed by 144.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 15,445 shares of the medical equipment provider's stock worth $1,487,000 after purchasing an additional 9,136 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of iRadimed by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider's stock worth $21,768,000 after purchasing an additional 9,017 shares during the last quarter. Institutional investors own 92.34% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IRMD. Wall Street Zen lowered iRadimed from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Weiss Ratings lowered iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $120.00.

Insiders Place Their Bets

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the business's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the transaction, the chief executive officer owned 2,162,500 shares in the company, valued at approximately $195,922,500. The trade was a 0.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 34.60% of the stock is owned by insiders.

iRadimed Stock Down 0.5%

iRadimed stock opened at $87.55 on Wednesday. iRadimed Corporation has a 52-week low of $67.84 and a 52-week high of $107.90. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of 48.91 and a beta of 0.90. The firm has a 50-day moving average price of $93.87 and a two-hundred day moving average price of $94.70.

iRadimed (NASDAQ:IRMD - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Research analysts expect that iRadimed Corporation will post 1.98 earnings per share for the current year.

iRadimed Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 28th. Investors of record on Friday, August 14th will be given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date is Friday, August 14th. iRadimed's dividend payout ratio (DPR) is currently 44.69%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRadimed Corporation (NASDAQ:IRMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source